Elevated Prevalence Of Skin Infections Fuels Growth In The Acute Bacterial Skin And Skin Structure Infections Market: A Significant Driver Propelling The Acute Bacterial Skin And Skin Structure Infections Market In 2025

The Acute Bacterial Skin And Skin Structure Infections Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Acute Bacterial Skin And Skin Structure Infections Market Size and Projected Growth Rate?
In the last few years, the market size for acute bacterial skin and skin structure infections has seen swift expansion. The market is set to grow from $11.75 billion in 2024 to $13.03 billion in 2025, with a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth in the historical period include advances in the healthcare industry, economic conditions, demographic patterns among patients, advances in diagnostic techniques, and innovative clinical trials.

The market for acute bacterial skin and skin structure infections is anticipated to observe robust expansion in the coming years, reaching $18.99 billion in 2029 at a 9.9% compound annual growth rate (CAGR). The projected growth in this period can be ascribed to worldwide epidemiological conditions, the introduction of new treatment methods, swift diagnostic instruments, a patient-focused approach, and evolving treatment guidelines. Key trends during the forecast period will consist of changes in patient population demographics, heightened concerns about antibiotic resistance, progress in treatment tactics, the spread of methicillin-resistant Staphylococcus aureus (mrsa), and an increased emphasis on outpatient treatment.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13282

What Are the Major Segments in the Acute Bacterial Skin And Skin Structure Infections Market?
The acute bacterial skin and skin structure infections market covered in this report is segmented -

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route Of Administration: Oral, Parenteral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Subsegments:
1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices
2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

What Are The Driving Acute Bacterial Skin And Skin Structure Infections Market Evolution?
An anticipated increase in skin infection incidents is likely to fuel further development in the acute bacterial skin and skin structure infections market. The term skin infections depicts situations where invaders such as bacteria, fungi or viruses spread and reproduce within the skin, causing varied symptoms and discomfort. The growing rate of skin infections demands better therapeutic solutions, innovative treatments, and antibiotics to treat severe bacterial skin and skin structure infections, ensuring patients receive superior care and results. For example, the World Health Organization, a Switzerland-based specialized UN agency, reported in March 2023 that approximately 1.8 billion people worldwide experience skin ailments. Among these, neglected tropical diseases (NTDs) account for about 10%, fungal infections 34%, and bacterial infections 23%, all of which have high mortality rates. Thus, the escalating prevalence of skin infections is predicted to stimulate the acute bacterial skin and skin structure infections market. The rise in chronic diseases is forecasted to further stimulate the acute bacterial skin and skin structure infections market's evolution. Chronic ailments are usually long-term medical problems that progress slowly and linger over an extended duration. They are typically persistent, lasting years or even a lifetime, and rarely resolve on their own. The surge in chronic diseases propels the acute bacterial skin and skin structure infections market by increasing the risk of bacterial skin infections. Subsequently, this leads to a rise in treatments, hospitalizations, specialized care, research, public cognizance, healthcare expenditure, and personalized interventions for affected individuals. For example, the World Health Organization, a Swiss-based specialized UN agency, reported in September 2022 that 41 million deaths linked to non-communicable diseases (NCDs) or chronic diseases occur annually worldwide. Among them, cardiovascular diseases claimed 17.9 million lives, cancer 9.3 million, chronic respiratory diseases 4.1 million, and diabetes 2.0 million. As such, the swelling prevalence of chronic diseases is expected to push growth in the acute bacterial skin and skin structure infections market.

Which Firms Dominate The Acute Bacterial Skin And Skin Structure Infections Market Segments?
Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

What Trends Are Expected to Dominate the Acute Bacterial Skin And Skin Structure Infections Market in the Next 5 Years?
Leading players in the Acute Bacterial Skin and Skin Structure Infections market are striving to innovate single-dose treatments, like Dalbonova, in order to gain a competitive advantage. Dalbonova is a unique one-time therapy providing convenience and effectiveness, enabling patients to attain the desired results with only a single potent dose of 1500 mg given once. For instance, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., a company based in India that specializes in API (active pharmaceutical ingredient) and formulation therapeutic sectors, including acute bacterial skin and skin structure infections, introduced Dalbonova injection, a one-time treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This injection helps prevent hospital-acquired diseases by providing one dose treatment and removing the requirement for hospital stays. It's crafted to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain gram-positive organisms in patients across all age groups, including newborns.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

Which Is The Largest Region In The Acute Bacterial Skin And Skin Structure Infections Market?
Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acute Bacterial Skin And Skin Structure Infections Market?
2. What is the CAGR expected in the Acute Bacterial Skin And Skin Structure Infections Market?
3. What Are the Key Innovations Transforming the Acute Bacterial Skin And Skin Structure Infections Industry?
4. Which Region Is Leading the Acute Bacterial Skin And Skin Structure Infections Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.